View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
J Eur Acad Dermatol Venereol 2025;39:1631–42 https:// doi. org/ 10. 1111/ jdv. 20828
This study by Lluch-Galcerá et al. provides valuable RWE to inform personalized clinical decision-making in the treatment of PsO. Authors evaluated the incidence of MACE associated with each systemic treatment used for patients with PsO and compared these rates to those observed with MTX.
Alimentary Pharmacology & Therapeutics 2025;62:483–492 Doi: 10.1111/apt.70264
Danese et al. showed that patients who achieved disease clearance 8 weeks after ustekinumab induction were more likely to be in long-term clinical, symptomatic and quality of life remission with ustekinumab maintenance treatment than patients who did not. Authors evaluated disease clearance in the Phase 3 UNIFI program and its association with long-term outcomes.
Ther Adv Gastroenterol 2025;18:1–11 Doi: 10.1177/17562848251367559
In patients with UC and refractory spondyloarthritis (SpA)—many of whom had previously failed multiple biologic therapies—TOF demonstrated effectiveness, particularly in those with peripheral SpA. Macaluso et al. assessed the effectiveness of TOF in UC-associated SpA. Articular responses were evaluated using rheumatologic scores.
J Dermatol 2025 Doi: 10.1111/1346-8138.17906 Epub ahead of print
Wang et al. validated the effectiveness and safety of UPA in this real-world study of Chinese PsA patients. UPA demonstrated comparable effectiveness to secukinumab (SEC) in psoriatic lesion improvement while showing comparable joint symptom relief compared with adalimumab (ADA), coupled with a favourable safety profile.
RMD Open 2025;11:e005522 Doi:10.1136/rmdopen-2025-005522
Treatment with risankizumab provides durable improvement in the signs and symptoms of PsA across all the GRAPPA disease domains and related conditions. This post hoc analysis by Coates et al. aimed to assess the efficacy of long-term treatment with risankizumab across the updated GRAPPA domains and key related conditions of PsA.
RMD Open 2025;11:e005-21 Doi: 10.1136/rmdopen-2025-005521
Most patients vaccinated with RZV while using UPA 15mg QD and background MTX achieved satisfactory humoral and cell-mediated immune responses to recombinant zoster vaccine (RZV) at Weeks 4, 16 and 60. Winthrop et al. evaluated the immunogenicity of RZV through Week 60 in patients with RA who were receiving UPA 15mg QD and background MTX.
Gastroenterology 2025;169:308–25 Doi: 10.1053/j.gastro.2025.02.033
Results from the Phase 3 GRAVTI study by Hart et al. showed that SC induction followed by SC maintenance treatment with guselkumab resulted in superior clinical and endoscopic improvements in participants with moderately to severely active CD through 48 weeks compared with placebo. Hart et al. evaluated efficacy and safety of guselkumab SC induction followed by SC maintenance in participants with moderately to severely active CD in a treat-through design.
Clin Exp Dermatol 2025;50:1786–1794 Doi: 10.1093/ced/llaf172
This study by Mortato et al. enhanced the limited safety data on guselkumab in patients with moderate-to-severe plaque psoriasis who have clinically relevant infectious and oncological comorbidities as well as concomitant heart disease. Authors assessed clinical outcomes and safety of guselkumab in a large cohort of patients with concomitant chronic infection, cancer or heart disease over a long follow-up period, addressing critical gaps in clinical evidence.
Rheumatol Ther 2025; Epub ahead of print doi: 10.1007/s40744-025-00786-2
Baraliakos et al. compared real-world effectiveness of upadacitinib, TNF inhibitors, or IL-17 inhibitors following inadequate response to an initial TNF inhibitor in patients with axSpA. Upadacitinib was associated with greater reductions in pain and fewer affected joints compared with switching to a second TNF inhibitor or IL-17 inhibitor.
RMD Open 2025;11:e005806 doi: 10.1136/rmdopen-2025-005806
In this nationwide observational study, ixekuzumab was mainly used in patients with axSpA and PsA who had previously failed multiple b/tsDMARDs, including other IL-17 inhibitors. Although prior IL-17 treatment was associated with increased risk of withdrawal in both groups, the relatively high retention rates and improvements in all disease outcomes suggest ixekizumab as a viable option for challenging patients with multiple b/tsDMARD failures.
